There are currently 412 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Spectrum Health - Butterworth Campus, Trinity Health Grand Rapids Hospital and CCOP - Grand Rapids. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan +2 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583
Recruiting
The Study is a Phase 3, randomized, three-arm, double-blind, placebo-controlled, multi-regional clinical research study to evaluate the safety and efficacy use of toripalimab alone or in combination with tifcemalimab as consolidation therapy in patients with limited-stage small cell lung cancer without disease progression following chemoradiotherapy. Tifcemalimab is a monoclonal antibody against B and T lymphocyte attenuator (BTLA). Toripalimab is a monoclonal antibody against programmed death... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan
Conditions: Limited-stage Small Cell Lung Cancer (LS-SCLC)
Register for Updates
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706
Recruiting
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \[primary resistance\]) or relapsed \[secondary resistance\]) after at least 3 months from... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: South Texas Accelerated Research Therapeutics (START), Grand Rapids, Michigan
Conditions: Metastatic Solid Tumor
Register for Updates
Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)
NCT03926520
Recruiting
This study will explore the effect of ECT treatments plus usual care (ECT+UC) in reducing severe agitation in patients with moderate to severe dementia including Alzheimer's Disease, Vascular dementia, Frontotemporal dementia, and Dementia with Lewy Bodies. The study will also determine the tolerability/safety outcomes of ECT+UC.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/30/2024
Locations: Pine Rest Christian Mental Health Services, Grand Rapids, Michigan
Conditions: Alzheimer Dementia, Agitation,Psychomotor
Register for Updates
Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies
NCT04092673
Recruiting
This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of Zotatifin (eFT226) in subjects with selected advanced solid tumor malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor, Adult
Register for Updates
Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors
NCT06086522
Recruiting
Goal: learn about QN-302 in patients with solid tumors (metastatic, or advanced cancer). Main questions: * What does the study drug do to human body (Pharmacodynamics \[='PD'\]) * What does the body do to study drug (how processed in body (Pharmacokinetics \[='PK'\]) - Safety Study drug by intravenous infusion ('IV') once weekly for 3 weeks every 4-week 'cycle.' Study treatment continues as long as patient and their study doctor agree that study treatment is in the best interest of the patien... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumor
Register for Updates
Study of Efficacy of the MyoTrain System in a Population of Individuals With Trans-radial Limb Loss
NCT05888428
Recruiting
The investigators propose to evaluate the efficacy of MyoTrain in a prospective clinical study involving 16 individuals with trans-radial upper-limb loss over a period of 206 days. These individuals will be randomized to Group A (Control Group using standard motor imagery training) and Group B (who are provided the MyoTrain system). The investigators will test three hypotheses: 1. The use of MyoTrain results in skills transference to control of the final prosthesis 2. The virtual outcome measu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Hanger Clinic - Grand Rapids, Grand Rapids, Michigan
Conditions: Amputation, Upper Limb
Register for Updates
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation
NCT01656603
Recruiting
This study will evaluate the safety of infusion of the investigational cord blood units by carefully documenting all infusion-related problems.
Gender:
ALL
Ages:
All
Trial Updated:
04/17/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Infusion Reactions
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: COVID-19
Register for Updates
Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment
NCT04880473
Recruiting
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
03/11/2024
Locations: Spectrum Health Blodgett Hospital, Grand Rapids, Michigan
Conditions: Gastrointestinal Complication
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Corewell Heath Butterworth Hospital, Grand Rapids, Michigan
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
Study of ON 123300 in Patients With Advanced Cancer
NCT04739293
Recruiting
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Solid Tumors, Adult
Register for Updates